Instil Bio, Inc. (TIL)
Instil Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Dallas, TX, US. The stock last traded at $7.49, up 1.08% on the session, giving a market capitalisation of $50.8M. On trailing twelve-month figures it carries a trailing P/E of -1.06, a net margin of 0.0%. Its beta of 1.91 implies it has historically moved more than the broad market.
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.
Instil Bio, Inc. is most often compared with the following Healthcare names: